Director/PDMR Shareholding
October 27, 2015 13:50 ET
|
AstraZeneca PLC
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 27 October 2015, Jean-Philippe Courtois, a Director of the Company notified
us that, on 6 August 2015, he...
FDA ADVISORY COMMITTEE RECOMMENDS THE APPROVAL OF LESINURAD FOR GOUT PATIENTS
October 26, 2015 03:00 ET
|
AstraZeneca PLC
AstraZeneca has announced that the US Food and Drug Administration's
(FDA) Arthritis Advisory Committee (AAC) voted 10 to 4 to recommend the approval
of lesinurad 200mg tablets for the treatment of...
AstraZeneca Receives Complete Response Letter from US FDA for SaxaGLIPTIN / dapaGLIFLOZIN Fixed-Dose-Combination
October 16, 2015 02:00 ET
|
AstraZeneca PLC
AstraZeneca (http://www.astrazeneca.com/) today announced that the US Food and
Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding
the New Drug Application (NDA) for the...
Holding(s) in Company - Amendment
October 08, 2015 13:31 ET
|
AstraZeneca PLC
The 'Holding(s) in Company' announcement released on 08 October 2015 at 17.29
was released in error and should be disregarded....
Holding(s) in Company
October 08, 2015 11:29 ET
|
AstraZeneca PLC
Please refer the pdf attachment....
ASTRAZENECA COMPLETES DIVESTMENT OF CAPRELSA
October 07, 2015 02:00 ET
|
AstraZeneca PLC
ASTRAZENECA COMPLETES DIVESTMENT OF RARE DISEASE MEDICINE CAPRELSA
AstraZeneca has announced the global completion of the divestment of Caprelsa®
(vandetanib), a rare disease medicine, to Genzyme, a...
Director/PDMR Shareholding
October 01, 2015 09:00 ET
|
AstraZeneca PLC
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 1 October 2015, the interest of Mr Pascal Soriot, a person discharging
managerial responsibilities, in the...
Director/PDMR Shareholding
September 28, 2015 09:30 ET
|
AstraZeneca PLC
Transactions by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 25 September 2015, Dr Sean Bohen, EVP, Global Medicines Development & Chief
Medical Officer, a person...
Director/PDMR Shareholding
September 28, 2015 09:30 ET
|
AstraZeneca PLC
Transactions by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 28 September 2015, Marc Dunoyer, Chief Financial Officer, a person
discharging managerial responsibilities,...
US FDA APPROVES EXPANDED INDICATION FOR BRILINTA TO INCLUDE LONG-TERM USE IN PATIENTS WITH A HISTORY OF HEART ATTACK
September 04, 2015 02:00 ET
|
AstraZeneca PLC
AstraZeneca today announced that the US Food and Drug Administration (FDA) has
approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used in
patients with a history of heart attack beyond...